A high-performance liquid chromatographic method was developed for the measurement of carbamazepine (CBZ) and carbamazepine 10,11-epoxide (CBZE) in human breast milk and plasma. The method involves rapid C 18 solidphase extraction of CBZ and CBZE. Chromatographic separation was achieved with a reversed-phase C 8 column using a mobile phase of potassium dihydrogenphosphate (pH 2´5) and acetonitrile (67:33 v/v), with ultraviolet detection at 254 nm. 2-Methyl CBZ was used as the internal standard. Determination of both CBZ and CBZE was possible in the range of 0´01±6´0 mg/L and 0´02±6´0 mg/L in milk and plasma, respectively. The recoveries of CBZ and CBZE added to the milk and plasma were 90´6±98.0% and 88´9±104´0%, respectively, with coef®cients of variation less than 8´3% and 10´5%, respectively. The method has been used for drug level monitoring in milk and plasma samples obtained from CBZ-treated patients. The mean (SD) levels for CBZ in milk and plasma samples were 3´50 (0´4) mg/L and 6´18 (2´9) mg/L, and for CBZE were 1´28 (0´3) mg/L and 1´85 (1´0) mg/L, respectively. The mean (SD) milk/plasma ratios of CBZ and CBZE were 0´64 (0´2) and 0´79 (0´3), respectively. The milk/plasma ratio of CBZE was slightly higher than that of CBZ.
Human breast milk is the optimal food for infant nutrition. The motivation for breast feeding has increased and has been popularized all over the world. In general, breast feeding increases the mother's sense of caring for her baby, and physicians should encourage mothers to breast feed. It is usually necessary for antiepileptic drugs to be continued throughout pregnancy and lactation, 1 and as a result the antiepileptic drugs are either transferred to foetal blood or secreted into the breast milk. Therefore, the breast-fed infant's risk of exposure to antiepileptic drugs must be considered. Adverse effects of antiepileptic drugs upon infants have been reported, because the activity of drug-metabolizing enzymes in infants is lower than in adults. Monitoring of drug levels in maternal milk, therefore, is necessary to prevent adverse drug effects when breast feeding.
Carbamazepine has been widely used in the treatment of epilepsy and trigeminal neuralgia. It is converted to the CBZE metabolite, which also has anticonvulsant activity. 2 The monitoring of both CBZ and CBZE in the breast milk of CBZ-treatment patients may be useful to prevent side effects in the infant. Although CBZ and CBZE levels in the milk have been reported in previous papers, 3±5 all of these subjects were Caucasian. Data on CBZ in Japanese patients' breast milk have been reported previously only once, 6 and more data on drug concentration in Japanese patients' breast milk are needed to safeguard infants being breast-fed by Japanese mothers who are treated with carbamazepine.
Several high-performance liquid chromatographic methods have been described for the analysis of CBZ and CBZE in breast milk and plasma. 4,5,7±9 However, these methods involve a liquid±liquid extraction procedure which is tedious and unsystematic. Herkes et al. 8 reported analysis of CBZ and CBZE in human saliva by preparation with acetonitrile precipitation. However, this method causes column damage. Hartley et al. 9 have reported analysis of CBZ and CBZE in human saliva by the Bond-Elute C 18 extraction method. We tried this method preliminarily by Sep-Pak C 18 cartridge extraction from the breast milk. However, we could not obtain satisfactory recovery and good chromatogram results by this method.
Recently, we developed a C 18 bonded solidphase extraction method for several drugs in the breast milk. 10±12 These methods are simple and quick. However, there have been no previous papers describing the solid-phase extraction method of CBZ and CBZE in breast milk. In this paper, we describe a rapid and simple highperformance liquid chromatography (HPLC) method for the determination of CBZ and CBZE levels in milk and plasma and show pharmacokinetic data from seven epileptic Japanese patients who were being treated with CBZ.
SAMPLES AND METHODS

Materials
Supplies of CBZ and CBZE were kindly donated by NOVARTIS (Tokyo, Japan). 2-Methyl CBZ was obtained from Aldrich Chemical Company Inc (Milwaukee WI, USA). Sep-Pak C 18 cartridges were purchased from Waters Chromatography, Millipore Co (Milford MA, USA). All other solvents used were of HPLC grade (Wako Pure Chemical Industries, Osaka, Japan). All other reagents and chemicals were purchased from Wako Pure Chemical Industries or Nakarai Tesque (Kyoto, Japan).
Subjects
Seven lactating women with a mean age of 28 years (range 24±34 years) and mean body weight of 52 kg (range 40±72 kg) participated in the study. All patients were receiving CBZ, and patients 3 and 5 also received antipsychotic drugs. Breast milk and plasma samples were collected for treatment purposes. All patients gave informed consent for the clinical examinations. The infants were clinically observed for neonatal behaviour problems such as vomiting, sedation and withdrawal symptoms.
Drug analysis
The concentrations of CBZ and CBZE in the milk and plasma were measured by HPLC using an ultraviolet detection method developed in our laboratory. The HPLC system consisted of a Philips, Pye Unicam PU 4010 pump with Pye Unicam PU 4020 UV detector at 254 nm (Pye Unicam Ltd, Cambridge, UK) and a Rheodyne model 7125 injector (Rheodyne Inc, Cotati, CA, USA). Separation was accomplished on a C 8 stationary phase column (Develosil C 8 , 150 4´6 mm I.D.; Nomura Chemicals, Seto, Japan) using a¯ow rate of 1´0 mL/min at ambient temperature. The mobile phase consisted of 0´5% potassium dihydrogen phosphate (pH 2´5)±acetonitrile (67:33, v/v).
Sample preparation
2-Methyl CBZ (90 ng) in methanol (10 L) was added to breast milk or plasma samples (1 mL) as an internal standard. Milk samples were then diluted with 5 mL of 50 mmol/L phosphate buffer (pH 9´0) and plasma samples were diluted with 5 mL of 50 mmol/L phosphate buffer (pH 10´0), and both were brie¯y mixed. These mixtures were applied to a Sep-Pak C 18 cartridge, washed with 5 mL of water and 20% methanol and the desired fraction was then eluted with 60% methanol (5 mL). The extrac-tion¯ow rate in each step on the Sep-Pak C 18 cartridge was not controlled. The eluate was evaporated and the residue was dissolved in the mobile phase and then injected into the HPLC.
Calibration curves and recovery experiment
Known amounts of CBZ and CBZE in the concentration ranges 0´01±6´0 mg/L and 0´02± 6´0 mg/L were added to drug-free milk or plasma samples, respectively. These samples were treated according to the extraction procedure described above. The peak-height ratios of CBZ and CBZE to 2±methyl CBZ were measured and plotted appropriately against the concentration of eluate. Recovery experiments were carried out by adding six levels of known amounts of CBZ and CBZE to drug-free samples. These samples were extracted by the method described above. The control samples were not extracted but were directly evaporated and the residues were reconstituted in the mobile phase. An external standard (instead of the internal one) was added before sample evaporation. Recoveries were determined by comparison between the solid-phase extraction and non-extraction control. The method validation was determined by calibration and recovery experiments. The recovery was calculated as the percentage of the nominal concentration: re-covery=observed concentration/nominal concentration 100. The between-run coef®cient of variation was calculated from measurement on six separate days. The within-run coef®cient of variation was derived from analysis of six quality control samples at each concentration on the same day. All calibration curves were required to have a correlation value of at least 0´99. The detection limit was de®ned as the quantity of the sample after preparation and extraction which had a coef®cient of variation of less than 20%. (Signal-to-noise ratio=5´0.)
RESULTS
The typical chromatograms of drug-free breast milk and plasma-spiked with 2-methyl CBZ, breast milk from CBZ-treated patients and plasma from CBZ-treated patients are shown in ®g. 1. The separation of CBZ, CBZE and 2-methyl CBZ was obtained satisfactorily and the isolation of interfering peaks in biological matrix from the analysed peaks was then established by our extraction method and chromatographic system. Calibration curves for CBZ and CBZE in the milk and plasma were linear in the concentration range 0´01± 6´0 mg/L (for CBZ) and 0´02±6´0 mg/L (for CBZE). The limit of detection for both CBZ and CBZE was 5 g/L.
The results of recovery studies are shown in Table 1 . The recoveries of both CBZ and CBZE were determined by adding six known concentrations of 0´04, 0´08, 0´12, 0´5, 2 and 5 mg/L to drug-free milk and plasma. The recovery values for CBZ were 91´1±98´0% in milk and 90´6± 97´1% in plasma in the concentration range 0´04±5´0 mg/L. The recovery values for CBZE were 88´9±99.5% in milk and 92´1±104´0% in plasma. Both within-run and between-run assay variations for CBZ were less than 5´8% in milk and less than 8´3% in plasma. Both within-run and between-run assay variations for CBZE were less than 10´5% in milk and less than 9´6% in plasma. The accuracy and precision of the proposed method were de®ned from these results.
The concentrations of CBZ and CBZE in breast milk and plasma samples from CBZtreated patients were measured using our present method. The levels of CBZ in patients who received CBZ at doses of 250±800 mg/day were at 2´8±4´5 mg/L in milk and 3´2±15´0 mg/L in plasma. The levels of the CBZE were 0´5±1´7 mg/L in milk and 0´8±4´8 mg/L in plasma (see Table 2 ). Samples having high drug concentrations beyond the range of our present method were measured after sample dilution. Breast milk versus plasma concentration ratios ranged from 0´25±1´2 for CBZ [mean (SD): 0´64 (0´2)] and 0´27±1´7 for CBZE [mean (SD): 0´79 (0´3)]. The plasma concentrations of CBZ and CBZE increased with time postpartum, but the milk concentrations of CBZ and CBZE decreased in patient 6 (see Table 2 , Fig. 2 ).
DISCUSSION
The method presented here is rapid, speci®c and sensitive enough to allow simultaneous quantitation of both CBZ and CBZE in the milk and plasma of patients being treated with CBZ during lactation. In previous methods using HPLC, 10-methoxy CBZ, 8 nitrazepam, 9 5-(p-methylphenyl)-5-phenylhydantoin, 5 N-desmethyldiazepam and lorazepam 7 were used as internal standards. Presumably, 10-methoxy CBZ is one of the most suitable internal standards, but this compound is not commercially available. In the present method, we used commercially available 2-methyl CBZ as an internal standard. 2-methyl CBZ has the same ±  3´7  15´0  0´25  1´3  4´8  0´27  2  800  1  4´5  6´0  0´75  1´5  2´0  0´75  2  800  2  3´5  5´2  0´67  1´5  1´9  0´79  2  800  3  3´7  7´7  0´48  1´5  2´4  0´63  3  500  2  3´4  5´3  0´64  0´5  1´1  0´45  4  400  3  3´4  4´0  0´85  0´8  0´8  1´00  5  250  3  3´4  5´6  0´61  1´4  1´6  0´88  6  600  5´1 (cord blood)  6  600  3  3´8  3´2  1´20  1´7  1´0  1´70  6  600  5  2´8  4´9  0´57  1´3  1´5  0´87  6  600  10  2´8  5´4  0´52  1´0  1´7  0´59  6  600  34  3´4  6´1  0´56  1´2  1´7  0´71  7  500  1  3´5  5´3  0´66  1´5  1´7  0´88  7 500
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extraction ef®ciency and chromatographic properties as CBZ and CBZE.
In preliminary experiments of sample extraction, we tried the previous solid-phase extraction method, 9 which did not give a satisfactory recovery. Therefore, we examined sample extraction by Sep-Pak C 18 cartridges using alkaline conditions. The extraction recoveries of CBZ and CBZE from the milk were about 72±85% at pH 7´0, 82±90% at pH 8´0 and 89±99% at pH 9´0. The extraction recoveries in plasma were 66±81% at pH 8´0, 73±84% at pH 9´0 and 92±104% at pH 10´0. The highest recoveries of CBZ and CBZE were obtained at pH 9´0 in milk and at pH 10´0 in plasma. The stability of octadethyl stationary phase in Sep-Pak C 18 cartridges under alkaline conditions was checked by a recovery test after repeated washing with alkaline solution. We had reported previously drug extraction methods for milk and plasma using Sep-Pak C 18 cartridges under alkaline conditions. 10±12 Therefore, we achieved high extraction ef®ciency with no interfering peaks from endogenous substances on the chromatogram (see ®g. 1). The present assay method enabled measurement of CBZ and CBZE concentrations in the ranges 0´01±6 mg/L and 0´02±6 mg/L, respectively. The limit of detection is lower than in previous papers. 7±9 The mean (SD) percentage of CBZ in milk was 64 (20)% lower than the plasma level, which is lower than in previous reports. 4±6 On the other hand, our results agreed with those obtained by Pynnonen and Sillanpaa, 3 who reported a mean value in milk 60% that of plasma, based on three patients. The relationship between milk and plasma concentrations of CBZ was not determined in our study. In a previous paper, Kaneko et al. 13 described a good correlation between milk and serum CBZ concentrations (r=0´79). However, a signi®cant correlation was not observed between CBZ (r=0´17) and CBZE (r=0´23) in the present study. Froescher et al. 5 observed no signi®cant correlation between the concentrations of CBZ in milk and serum.
In the present study, the milk/plasma ratio declined over the postpartum period in patient 6 (see table 2, ®g. 2). This phenomenon may be due to the increasing level of fat and the decreasing level of protein present in milk over the postpartum period. 14 affected by the falling protein concentration in milk. CBZE was about 20% lower in milk than in plasma in our study, which is higher than that reported by Kuhnz et al., 4 but lower than that reported by Pynnonen and Sillanpaa. 3 The difference cannot be explained. However, higher clearance values of CBZ during pregnancy, although not reaching a statistically signi®cant level, have been described by Bardy. 15 The plasma levels of CBZ and CBZE in patient 6 increased daily after parturition, (see Table 2 , ®g. 2), but the CBZE/CBZ ratios did not change with postpartum days. The results in patient 6 may be due to the decrease in renal clearance and the decrease in blood volume that occur in the postpartum period. Further study is needed to examine whether this is a general rule. Based on our present results, a 4 kg infant taking 0´5 L breast milk per day would ingest approximately 1´5±3´5 mg (0´37±0´87 mg/kg) CBZ and 0´25±0´82 mg (0´062±0´212 mg/kg) CBZE from a lactating mother being treated with standard doses of CBZ. The pharmacological effects of such drug intakes are probably not signi®cant in infants, these doses being lower than the therapeutic range. However, drug levels in milk should be monitored when CBZ is given during lactation, in order to prevent adverse effects in the event of high CBZ intakes.
